| Cavia porcellus |
Kappa opioid receptor |
Ki |
325.0 |
nM |
10.1016/j.ejmech.2019.05.037 |
| Cavia porcellus |
Kappa opioid receptor |
Ki |
10000.0 |
nM |
10.1016/j.bmc.2010.05.071 |
| Electrophorus electricus |
Acetylcholinesterase |
IC50 |
76200.0 |
nM |
10.1016/j.bmc.2010.05.071 |
| Electrophorus electricus |
Acetylcholinesterase |
Inhibition |
80.0 |
% |
10.1016/j.bmc.2010.05.071 |
| Homo sapiens |
Adenosine A1 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Adenosine A2a receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Adenosine A3 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Alpha-1a adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Alpha-2a adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Alpha-2b adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Aryl hydrocarbon receptor |
Activity |
nan |
None |
10.1124/dmd.112.050401 |
| Homo sapiens |
Beta-1 adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Beta-2 adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Bradykinin B2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cannabinoid CB1 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cholecystokinin A receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cholecystokinin B receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cyclooxygenase-2 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Delta opioid receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Delta opioid receptor |
EC50 |
4000.0 |
nM |
10.1016/j.bmcl.2013.06.084 |
| Homo sapiens |
Delta opioid receptor |
Inhibition |
93.0 |
% |
10.1016/j.bmcl.2013.06.084 |
| Homo sapiens |
Dopamine D1 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Dopamine D2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Dopamine D3 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Dopamine transporter |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Endothelin receptor ET-A |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Equilibrative nucleoside transporter 1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Estrogen receptor alpha |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Ghrelin receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Glucocorticoid receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
HERG |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
HERG |
IC50 |
10000.0 |
nM |
10.1021/acs.jmedchem.0c01127 |
| Homo sapiens |
HERG |
Inhibition |
50.0 |
% |
10.1021/acs.jmedchem.0c01127 |
| Homo sapiens |
Histamine H1 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Histamine H2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Histamine H3 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Homo sapiens |
CL |
6.1 |
mL.min-1.kg-1 |
10.1021/jm900403j |
| Homo sapiens |
Homo sapiens |
CL_renal |
1.1 |
mL.min-1.kg-1 |
10.1021/jm900403j |
| Homo sapiens |
Homo sapiens |
DILI_Concern |
nan |
None |
10.1016/j.drudis.2016.02.015 |
| Homo sapiens |
Homo sapiens |
DILI_severity_class |
0.0 |
None |
10.1016/j.drudis.2016.02.015 |
| Homo sapiens |
Kappa opioid receptor |
AC50 |
2000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Kappa opioid receptor |
EC50 |
16000.0 |
nM |
10.1016/j.bmcl.2013.06.084 |
| Homo sapiens |
Kappa opioid receptor |
Inhibition |
47.0 |
% |
10.1016/j.bmcl.2013.06.084 |
| Homo sapiens |
Melanocortin receptor 3 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Monoamine oxidase A |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Motilin receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Mu opioid receptor |
AC50 |
230.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Mu opioid receptor |
AC50 |
29000.1 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Mu opioid receptor |
EC50 |
17.0 |
nM |
10.1021/acs.jmedchem.0c01127 |
| Homo sapiens |
Mu opioid receptor |
EC50 |
17.0 |
nM |
10.1021/acs.jmedchem.1c00417 |
| Homo sapiens |
Mu opioid receptor |
EC50 |
17.0 |
nM |
10.1021/acs.jmedchem.9b01256 |
| Homo sapiens |
Mu opioid receptor |
EC50 |
478.0 |
nM |
None |
| Homo sapiens |
Mu opioid receptor |
EC50 |
500.0 |
nM |
10.1016/j.bmcl.2013.06.084 |
| Homo sapiens |
Mu opioid receptor |
Emax |
100.0 |
% |
10.1021/acs.jmedchem.0c01127 |
| Homo sapiens |
Mu opioid receptor |
Emax |
100.0 |
% |
10.1021/acs.jmedchem.1c00417 |
| Homo sapiens |
Mu opioid receptor |
Emax |
100.0 |
% |
10.1021/acs.jmedchem.9b01256 |
| Homo sapiens |
Mu opioid receptor |
Inhibition |
93.0 |
% |
10.1016/j.bmcl.2013.06.084 |
| Homo sapiens |
Mu opioid receptor |
Ki |
12.0 |
nM |
10.1021/acs.jmedchem.0c01127 |
| Homo sapiens |
Mu opioid receptor |
Ki |
12.0 |
nM |
10.1021/acs.jmedchem.1c00417 |
| Homo sapiens |
Mu opioid receptor |
Ki |
12.0 |
nM |
10.1021/acs.jmedchem.9b01256 |
| Homo sapiens |
Mu opioid receptor |
Ki |
133.48 |
nM |
None |
| Homo sapiens |
Muscarinic acetylcholine receptor M1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Muscarinic acetylcholine receptor M2 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Muscarinic acetylcholine receptor M3 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Neuronal acetylcholine receptor protein alpha-4 subunit |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Neuropeptide Y receptor type 1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Norepinephrine transporter |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Nuclear receptor subfamily 1 group I member 3 |
Activity |
nan |
None |
10.1124/dmd.112.050401 |
| Homo sapiens |
Phosphodiesterase 3A |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Phosphodiesterase 4D |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Pregnane X receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Pregnane X receptor |
Activity |
nan |
None |
10.1124/dmd.112.050401 |
| Homo sapiens |
Progesterone receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 1a (5-HT1a) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 2a (5-HT2a) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 2b (5-HT2b) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 2c (5-HT2c) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 3a (5-HT3a) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin transporter |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Sigma opioid receptor |
Inhibition |
50.0 |
% |
10.1021/acs.jmedchem.0c01127 |
| Homo sapiens |
Sigma opioid receptor |
Inhibition |
50.0 |
% |
10.1021/acs.jmedchem.9b01256 |
| Homo sapiens |
Sigma opioid receptor |
Ki |
10000.0 |
nM |
10.1021/acs.jmedchem.0c01127 |
| Homo sapiens |
Sigma opioid receptor |
Ki |
10000.0 |
nM |
10.1021/acs.jmedchem.1c00417 |
| Homo sapiens |
Sigma opioid receptor |
Ki |
10000.0 |
nM |
10.1021/acs.jmedchem.9b01256 |
| Homo sapiens |
Solute carrier family 22 member 1 |
FC |
0.8 |
None |
10.1021/acs.jmedchem.9b01301 |
| Homo sapiens |
Solute carrier family 22 member 1 |
FC |
0.9 |
None |
10.1021/acs.jmedchem.9b01301 |
| Homo sapiens |
Solute carrier family 22 member 1 |
IC50 |
2003780.0 |
nM |
10.1021/acs.jmedchem.9b01301 |
| Homo sapiens |
Thromboxane A2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Type-1 angiotensin II receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
UDP-glucuronosyltransferase 1A4 |
Activity |
0.0 |
pm/min/mg |
10.1146/annurev.pharmtox.40.1.581 |
| Homo sapiens |
UDP-glucuronosyltransferase 2B15 |
Activity |
0.0 |
pm/min/mg |
10.1146/annurev.pharmtox.40.1.581 |
| Homo sapiens |
Vasopressin V1a receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Vasopressin V2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Whole blood |
Retention_time |
2.67 |
min |
10.1007/s00044-012-9977-1 |
| Mus musculus |
Constitutive androstane receptor |
Activity |
nan |
None |
10.1124/dmd.112.050401 |
| Mus musculus |
Kappa opioid receptor |
EC50 |
16000.0 |
nM |
10.1016/j.bmcl.2013.06.084 |
| Mus musculus |
Kappa opioid receptor |
Inhibition |
59.0 |
% |
10.1016/j.bmcl.2013.06.084 |
| Mus musculus |
Mu opioid receptor |
EC50 |
160.0 |
nM |
10.1016/j.bmcl.2013.06.084 |
| Mus musculus |
Mu opioid receptor |
Inhibition |
97.0 |
% |
10.1016/j.bmcl.2013.06.084 |
| Mus musculus |
Mus musculus |
Activity |
0.9 |
% |
10.1016/j.bmc.2015.03.049 |
| Mus musculus |
Mus musculus |
Activity |
3.9 |
% |
10.1016/j.bmc.2015.03.049 |
| Mus musculus |
Mus musculus |
Activity |
41.0 |
% |
10.1021/acs.jmedchem.1c00417 |
| Mus musculus |
Mus musculus |
Activity |
77.0 |
% |
10.1021/acs.jmedchem.1c00417 |
| Mus musculus |
Mus musculus |
Activity |
89.0 |
% |
10.1021/acs.jmedchem.1c00417 |
| Mus musculus |
Mus musculus |
Activity |
nan |
None |
10.1021/acs.jmedchem.9b01256 |
| Mus musculus |
Mus musculus |
ED50 |
0.38 |
mg.kg-1 |
10.1021/jm0580205 |
| Mus musculus |
Mus musculus |
ED50 |
0.94 |
mg.kg-1 |
10.1021/jm0580205 |
| Mus musculus |
Mus musculus |
ED50 |
1.3 |
mg.kg-1 |
10.1021/jm00225a021 |
| Mus musculus |
Mus musculus |
ED50 |
1.37 |
mg.kg-1 |
10.1021/jm0580205 |
| Mus musculus |
Mus musculus |
ED50 |
1.5 |
umol.kg-1 |
10.1021/jm00144a015 |
| Mus musculus |
Mus musculus |
ED50 |
4.0 |
mg.kg-1 |
10.1021/acs.jmedchem.1c00417 |
| Mus musculus |
Mus musculus |
ED50 |
4.3 |
mg.kg-1 |
10.1021/acs.jmedchem.9b01256 |
| Mus musculus |
Mus musculus |
Inhibition |
51.0 |
% |
10.1021/acs.jmedchem.0c01127 |
| Mus musculus |
Mus musculus |
MPE |
52.9 |
% |
10.1016/j.bmc.2015.03.049 |
| Mus musculus |
Mus musculus |
MPE |
63.3 |
% |
10.1016/j.bmc.2015.03.049 |
| Mus musculus |
Mus musculus |
MPE |
66.9 |
% |
10.1016/j.bmc.2015.03.049 |
| Mus musculus |
Mus musculus |
UI |
1.5 |
None |
10.1016/j.bmc.2015.03.049 |
| Rattus norvegicus |
Androgen Receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
Brain |
Fu |
0.66 |
None |
10.1124/dmd.110.035998 |
| Rattus norvegicus |
Brain |
Kp |
2.78 |
None |
10.1124/dmd.110.035998 |
| Rattus norvegicus |
Brain |
Vd |
4.2 |
L.kg-1 |
10.1124/dmd.110.035998 |
| Rattus norvegicus |
Brain |
Vdu |
4.2 |
ml |
10.1021/jm901036q |
| Rattus norvegicus |
Cannabinoid receptor |
Ki |
10000.0 |
nM |
10.1016/j.ejmech.2019.05.037 |
| Rattus norvegicus |
Cyclooxygenase-1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
Delta opioid receptor |
Ki |
487.0 |
nM |
10.1016/j.ejmech.2019.05.037 |
| Rattus norvegicus |
Delta opioid receptor |
Ki |
1087.0 |
nM |
10.1021/jm0580205 |
| Rattus norvegicus |
Delta opioid receptor |
Ki |
10000.0 |
nM |
10.1016/j.bmc.2010.05.071 |
| Rattus norvegicus |
GABA receptor alpha-1 subunit |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
Glutamate (NMDA) receptor subunit zeta 1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
Kappa opioid receptor |
Ki |
2658.0 |
nM |
10.1021/jm0580205 |
| Rattus norvegicus |
Mu opioid receptor |
EC50 |
25.0 |
nM |
10.1016/j.ejmech.2019.05.037 |
| Rattus norvegicus |
Mu opioid receptor |
Emax |
137.0 |
% |
10.1016/j.ejmech.2019.05.037 |
| Rattus norvegicus |
Mu opioid receptor |
Ki |
8.9 |
nM |
10.1016/j.ejmech.2019.05.037 |
| Rattus norvegicus |
Mu opioid receptor |
Ki |
43.6 |
nM |
10.1021/jm0580205 |
| Rattus norvegicus |
Mu opioid receptor |
Ki |
10000.0 |
nM |
10.1016/j.bmc.2010.05.071 |
| Rattus norvegicus |
Nuclear receptor subfamily 1 group I member 2 |
Activity |
nan |
None |
10.1124/dmd.112.050401 |
| Rattus norvegicus |
Opioid receptors; mu & delta |
Selectivity ratio |
25.0 |
None |
10.1021/jm0580205 |
| Rattus norvegicus |
Plasma |
Cp(f) |
0.33 |
uM |
10.1021/jm901036q |
| Rattus norvegicus |
Plasma |
Fu |
0.87 |
None |
10.1021/jm901036q |
| Rattus norvegicus |
Plasma |
K(p,uu,CSF) |
0.65 |
None |
10.1021/jm901036q |
| Rattus norvegicus |
Rattus norvegicus |
Activity |
40.0 |
g |
10.1016/j.ejmech.2019.05.037 |
| Rattus norvegicus |
Rattus norvegicus |
Activity |
43.0 |
g |
10.1016/j.ejmech.2019.05.037 |
| Rattus norvegicus |
Rattus norvegicus |
Activity |
nan |
None |
10.1016/j.ejmech.2019.05.037 |
| Rattus norvegicus |
Rattus norvegicus |
ED50 |
2.9 |
umol.kg-1 |
10.1021/jm00144a015 |
| Rattus norvegicus |
Rattus norvegicus |
K(p,uu,brain) |
3.0 |
None |
10.1124/dmd.110.036434 |
| Rattus norvegicus |
Voltage-gated L-type calcium channel alpha-1C subunit |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
IC50 |
19952.62 |
nM |
10.6019/CHEMBL4651402 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
IC50 |
20000.0 |
nM |
10.6019/CHEMBL4651402 |
| None |
ADMET |
Activity |
nan |
None |
10.1021/acs.jmedchem.0c01127 |
| None |
ADMET |
Activity |
nan |
None |
10.1021/acs.jmedchem.1c00417 |
| None |
ADMET |
Activity |
nan |
None |
10.1124/dmd.112.050401 |
| None |
ADMET |
BPR |
3.77 |
None |
10.1021/jm901036q |
| None |
ADMET |
CL |
6.1 |
mL.min-1.kg-1 |
10.1124/dmd.108.020479 |
| None |
ADMET |
Cmax |
50.0 |
nM |
10.1021/acs.jmedchem.9b01301 |
| None |
ADMET |
fCmax |
0.03 |
uM |
10.1021/acs.jmedchem.9b01301 |
| None |
ADMET |
fCmax |
0.54 |
uM |
10.1021/acs.jmedchem.9b01301 |
| None |
ADMET |
fCmax |
1.06 |
uM |
10.1021/acs.jmedchem.9b01301 |
| None |
ADMET |
Fu |
0.55 |
None |
10.1021/jm030408h |
| None |
ADMET |
K(p,uu,brain) |
1.03 |
None |
10.1021/jm901036q |
| None |
ADMET |
log10(%HIA +10) |
1.845 |
None |
10.1016/j.ejmech.2010.11.005 |
| None |
ADMET |
MRT |
6.8 |
hr |
10.1124/dmd.108.020479 |
| None |
ADMET |
T1/2 |
5.5 |
hr |
10.1124/dmd.108.020479 |
| None |
ADMET |
Vdss |
2.3 |
L.kg-1 |
10.1021/jm030408h |
| None |
ADMET |
Vdss |
2.5 |
L.kg-1 |
10.1124/dmd.108.020479 |
| None |
Hepatotoxicity |
HepSE_bilirubinemia |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_cholecystitis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_cholelithiasis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_cirrhosis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_Combined Scores |
1.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_elevated liver function tests |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_hepatic failure |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_hepatic necrosis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_hepatitis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_hepatomegaly |
1.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_jaundice |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_liver disease |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_liver fatty |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_liver function tests abnormal |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
NON-PROTEIN TARGET |
Fu |
0.55 |
None |
10.1124/dmd.108.020479 |
| None |
No relevant target |
Peff |
17.9 |
ucm/s |
10.1021/acs.jmedchem.9b01301 |
| None |
No relevant target |
pKa |
8.53 |
None |
10.1007/s11095-013-1232-z |
| None |
No relevant target |
pKa |
8.53 |
None |
10.1021/jm030408h |
| None |
No relevant target |
pKa |
9.1 |
None |
10.1124/dmd.110.035998 |
| None |
Unchecked |
EC50 |
51.0 |
nM |
10.1016/j.ejmech.2019.05.037 |
| None |
Unchecked |
Emax |
135.0 |
% |
10.1016/j.ejmech.2019.05.037 |
| None |
Unchecked |
Ratio |
1e-05 |
None |
10.1021/acs.jmedchem.9b01301 |
| None |
Unchecked |
Ratio |
0.0003 |
None |
10.1021/acs.jmedchem.9b01301 |
| None |
Unchecked |
Ratio |
0.001 |
None |
10.1021/acs.jmedchem.9b01301 |
| None |
Unchecked |
Ratio EC50 |
4.0 |
None |
10.1016/j.bmcl.2013.06.084 |
| None |
Unchecked |
Ratio EC50 |
32.0 |
None |
10.1016/j.bmcl.2013.06.084 |
| None |
Unchecked |
Ratio Ki |
37.0 |
None |
10.1016/j.ejmech.2019.05.037 |
| None |
Unchecked |
Ratio Ki |
55.0 |
None |
10.1016/j.ejmech.2019.05.037 |
| None |
Unchecked |
Selectivity ratio |
1.0 |
None |
10.1016/j.bmc.2010.05.071 |
| None |
Unchecked |
Selectivity ratio |
61.0 |
None |
10.1021/jm0580205 |